KRAS and non-small cell lung carcinoma: On May 28, 2021, the FDA granted accelerated approval to sotorasib (Lumakras, Amgen) for treating adults with advanced NSCLC carrying a KRAS G12C mutation who have undergone at least one prior systemic therapy (156).